Mark Sehgal, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1401 E Van Buren Ave, Mcalester, OK 74502 Phone: 918-421-8446 Fax: 918-423-4051 |
News Archive
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration approved KALYDECO® (ivacaftor) to include use in children with cystic fibrosis ages 12 to <24 months who have at least one mutation in their cystic fibrosis transmembrane conductance regulator gene that is responsive to KALYDECO based on clinical and/or in vitro assay data.
High-intensity interval training makes middle-aged people not only healthier but smarter, showed a Montreal Heart Institute (MHI) study led by Dr. Anil Nigam of the MHI and University of Montreal, in collaboration with the Montreal Geriatric University Institute.
Researchers at UPMC and the University of Pittsburgh have created a new, 5- to 10-minute test that could be added to a clinician's concussion evaluation toolkit for a more comprehensive assessment of the injury.
Almost half of patients with early stage breast cancer considered double mastectomy and one in six went ahead, including many who were only at a low risk of developing another breast cancer, according to a new study.
› Verified 3 days ago